

# Ricardo Dolcetti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7959414/publications.pdf>

Version: 2024-02-01

313  
papers

12,419  
citations

28274

55  
h-index

33894

99  
g-index

323  
all docs

323  
docs citations

323  
times ranked

15447  
citing authors

#	ARTICLE	IF	CITATIONS
1	Evidence for an Association Between Chlamydia psittaci and Ocular Adnexal Lymphomas. Journal of the National Cancer Institute, 2004, 96, 586-594.	6.3	533
2	Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 134-147.	2.5	513
3	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	21.4	493
4	High Prevalence of Activated Intraepithelial Cytotoxic T Lymphocytes and Increased Neoplastic Cell Apoptosis in Colorectal Carcinomas with Microsatellite Instability. American Journal of Pathology, 1999, 154, 1805-1813.	3.8	425
5	Association of Type and Location of BRCA1 and BRCA2 Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	7.4	390
6	Microsatellite Instability and High Content of Activated Cytotoxic Lymphocytes Identify Colon Cancer Patients with a Favorable Prognosis. American Journal of Pathology, 2001, 159, 297-304.	3.8	275
7	HLA-A11 epitope loss isolates of Epstein-Barr virus from a highly A11+ population. Science, 1993, 260, 98-100.	12.6	272
8	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	21.4	221
9	Hodgkin's disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors.. Journal of Clinical Oncology, 1995, 13, 1758-1767.	1.6	217
10	Characterization of Overt B-Cell Lymphomas in Patients With Hepatitis C Virus Infection. Blood, 1997, 90, 776-782.	1.4	217
11	Regression of Ocular Adnexal Lymphoma After Chlamydia Psittaci Eradicating Antibiotic Therapy. Journal of Clinical Oncology, 2005, 23, 5067-5073.	1.6	211
12	Bacteria-Eradicating Therapy With Doxycycline in Ocular Adnexal MALT Lymphoma: A Multicenter Prospective Trial. Journal of the National Cancer Institute, 2006, 98, 1375-1382.	6.3	201
13	Hepatitis C virus within a malignant lymphoma lesion in the course of type II mixed cryoglobulinemia. Blood, 1995, 86, 1887-1892.	1.4	174
14	Chlamydia Psittaci Eradication With Doxycycline As First-Line Targeted Therapy for Ocular Adnexal Lymphoma: Final Results of an International Phase II Trial. Journal of Clinical Oncology, 2012, 30, 2988-2994.	1.6	167
15	Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4. Journal of Virology, 1993, 67, 1572-1578.	3.4	164
16	Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease. Blood, 1995, 86, 1493-1501.	1.4	160
17	Human Herpesvirus 8 Is Present in the Lymphoid System of Healthy Persons and Can Reactivate in the Course of AIDS. Journal of Infectious Diseases, 1996, 173, 542-549.	4.0	159
18	High frequency of p53 gene alterations associated with protein overexpression in human squamous cell carcinoma of the larynx. Oncogene, 1992, 7, 1159-66.	5.9	149

#	ARTICLE	IF	CITATIONS
19	p53 over-expression is an early event in the development of human squamous-cell carcinoma of the larynx: Genetic and prognostic implications. <i>International Journal of Cancer</i> , 1992, 52, 178-182.	5.1	143
20	Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma. <i>Blood</i> , 2008, 111, 5142-5151.	1.4	142
21	Plasticity of Type I Interferon-Mediated Responses in Cancer Therapy: From Anti-tumor Immunity to Resistance. <i>Frontiers in Oncology</i> , 2018, 8, 322.	2.8	137
22	The epstein-barr virus latent membrane protein-1 (LMP1) induces interleukin-10 production in burkitt lymphoma lines. <i>International Journal of Cancer</i> , 1994, 57, 240-244.	5.1	132
23	Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies. <i>Cell</i> , 2020, 180, 895-914.e27.	28.9	127
24	Human Herpesvirus 6: A Survey of Presence and Variant Distribution in Normal Peripheral Lymphocytes and Lymphoproliferative Disorders. <i>Journal of Infectious Diseases</i> , 1994, 170, 211-215.	4.0	121
25	Virologic and Immunologic Evidence Supporting an Association between HHV-6 and Hashimoto's Thyroiditis. <i>PLoS Pathogens</i> , 2012, 8, e1002951.	4.7	121
26	Post-transplant lymphoproliferative disorders: From epidemiology to pathogenesis-driven treatment. <i>Cancer Letters</i> , 2015, 369, 37-44.	7.2	118
27	Human herpesviruses 6 and 7 in salivary glands and shedding in saliva of healthy and human immunodeficiency virus positive individuals. <i>Journal of Medical Virology</i> , 1995, 45, 462-468.	5.0	108
28	Lymphomas occurring specifically in HIV-infected patients: From pathogenesis to pathology. <i>Seminars in Cancer Biology</i> , 2013, 23, 457-467.	9.6	102
29	Characterization of prelymphomatous stages of B cell lymphoproliferation in Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 1997, 40, 318-331.	6.7	100
30	A lymphomagenic role for HIV beyond immune suppression?. <i>Blood</i> , 2016, 127, 1403-1409.	1.4	99
31	Congenital cytomegalovirus infection: patterns of fetal brain damage. <i>Clinical Microbiology and Infection</i> , 2012, 18, E419-E427.	6.0	96
32	Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy. <i>Annals of Oncology</i> , 2008, 19, 835-846.	1.2	93
33	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. <i>Nature Communications</i> , 2016, 7, 11375.	12.8	93
34	FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. <i>Human Molecular Genetics</i> , 2015, 24, 5345-5355.	2.9	91
35	The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders. <i>Haematologica</i> , 2010, 95, 1769-1777.	3.5	89
36	Chlamydia Infection and Lymphomas: Association Beyond Ocular Adnexal Lymphomas Highlighted by Multiple Detection Methods. <i>Clinical Cancer Research</i> , 2008, 14, 5794-5800.	7.0	83

#	ARTICLE	IF	CITATIONS
37	Pathogenetic and histogenetic features of HIV-associated Hodgkin's disease. <i>European Journal of Cancer</i> , 2001, 37, 1276-1287.	2.8	81
38	B lymphocytes and Epstein-Barr virus: The lesson of post-transplant lymphoproliferative disorders. <i>Autoimmunity Reviews</i> , 2007, 7, 96-101.	5.8	79
39	Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2012, 14, R33.	5.0	78
40	Simian-virus-40 footprints in human lymphoproliferative disorders of HIV <sup>-</sup> and HIV <sup>+</sup> patients. <i>International Journal of Cancer</i> , 1998, 78, 669-674.	5.1	75
41	Familial breast cancer: characteristics and outcome of BRCA 1 <sup>+</sup> positive and negative cases. <i>BMC Cancer</i> , 2005, 5, 70.	2.6	73
42	Self-adjuvanting nanoemulsion targeting dendritic cell receptor Clec9A enables antigen-specific immunotherapy. <i>Journal of Clinical Investigation</i> , 2018, 128, 1971-1984.	8.2	73
43	Clinical implications of hepatitis C virus infection in MALT-type lymphoma of the ocular adnexa. <i>Annals of Oncology</i> , 2006, 17, 769-772.	1.2	71
44	Epstein-Barr virus: Induction and control of cell transformation. <i>Journal of Cellular Physiology</i> , 2003, 196, 207-218.	4.1	69
45	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. <i>Human Molecular Genetics</i> , 2011, 20, 3304-3321.	2.9	68
46	Rituximab in patients with mucosal-associated lymphoid tissue-type lymphoma of the ocular adnexa. <i>Haematologica</i> , 2005, 90, 1578-9.	3.5	67
47	<i>Chlamydomonas reinhardtii</i> is viable and infectious in the conjunctiva and peripheral blood of patients with ocular adnexal lymphoma: Results of a single-center prospective case-control study. <i>International Journal of Cancer</i> , 2008, 123, 1089-1093.	5.1	66
48	Latent Membrane Protein 1 of Epstein-Barr Virus Activates the hTERT Promoter and Enhances Telomerase Activity in B Lymphocytes. <i>Journal of Virology</i> , 2008, 82, 10175-10187.	3.4	65
49	Improved Natural Killer cell activity and retained anti-tumor CD8 <sup>+</sup> T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy. <i>Journal of Translational Medicine</i> , 2015, 13, 204.	4.4	64
50	Proposed Molecular and miRNA Classification of Gastric Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1683.	4.1	64
51	Interleukin-10 and interleukin-18 promoter polymorphisms in an Italian cohort of patients with undifferentiated carcinoma of nasopharyngeal type. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 23-30.	4.2	63
52	Prevalence of <i>Borrelia burgdorferi</i> Infection in a Series of 98 Primary Cutaneous Lymphomas. <i>Oncologist</i> , 2011, 16, 1582-1588.	3.7	61
53	Molecular profile of Epstein-Barr virus infection in HHV-8-positive primary effusion lymphoma. <i>Leukemia</i> , 2000, 14, 271-277.	7.2	60
54	Role of HIV-1 matrix protein p17 variants in lymphoma pathogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 14331-14336.	7.1	58

#	ARTICLE	IF	CITATIONS
55	Chlamydial infection: the link with ocular adnexal lymphomas. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 658-669.	27.6	57
56	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2014, 16, 3416.	5.0	57
57	Immunophenotypic and molecular analyses of acquired immune deficiency syndrome-related and Epstein-Barr virus-associated lymphomas: A comparative study. <i>Human Pathology</i> , 1996, 27, 133-146.	2.0	56
58	Interplay among viral antigens, cellular pathways and tumor microenvironment in the pathogenesis of EBV-driven lymphomas. <i>Seminars in Cancer Biology</i> , 2013, 23, 441-456.	9.6	56
59	Local High-Dose Radiotherapy Induces Systemic Immunomodulating Effects of Potential Therapeutic Relevance in Oligometastatic Breast Cancer. <i>Frontiers in Immunology</i> , 2017, 8, 1476.	4.8	54
60	High-mobility-group (HMG) proteins and histone H1 subtypes expression in normal and tumor tissues of mouse. <i>FEBS Journal</i> , 1993, 213, 825-832.	0.2	53
61	Methylenetetrahydrofolate reductase 677 C→T polymorphism and risk of proximal colon cancer in north Italy. <i>Clinical Cancer Research</i> , 2003, 9, 743-8.	7.0	52
62	Prevalence of BRCA1 genomic rearrangements in a large cohort of Italian breast and breast/ovarian cancer families without detectable BRCA1 and BRCA2 point mutations. <i>Genes Chromosomes and Cancer</i> , 2006, 45, 791-797.	2.8	50
63	Epstein-Barr virus-associated Hodgkin's lymphoma in a rheumatoid arthritis patient treated with methotrexate and cyclosporin A. <i>Arthritis and Rheumatism</i> , 1995, 38, 867-868.	6.7	48
64	Association between <i>Helicobacter pylori</i> infection and MALT-type lymphoma of the ocular adnexa: clinical and therapeutic implications. <i>Hematological Oncology</i> , 2006, 24, 33-37.	1.7	48
65	Immunotherapy for Gastric Cancer: Time for a Personalized Approach?. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1602.	4.1	48
66	Re: Evidence for an Association Between <i>Chlamydia psittaci</i> and Ocular Adnexal Lymphomas. <i>Journal of the National Cancer Institute</i> , 2006, 98, 365-366.	6.3	47
67	Role of CD4 <sup>+</sup> Cytotoxic T Lymphocytes in the Control of Viral Diseases and Cancer. <i>International Reviews of Immunology</i> , 2010, 29, 371-402.	3.3	47
68	B cell clonality in gastric lymphoid tissues of patients with Sjogren's syndrome.. <i>Annals of the Rheumatic Diseases</i> , 1996, 55, 311-316.	0.9	46
69	Analysis and Significance of Anti-Latent Membrane Protein-1 Antibodies in the Sera of Patients with EBV-Associated Diseases. <i>Journal of Immunology</i> , 2000, 164, 2815-2822.	0.8	46
70	The impact of EBV and HIV infection on the microenvironmental niche underlying Hodgkin lymphoma pathogenesis. <i>International Journal of Cancer</i> , 2017, 140, 1233-1245.	5.1	46
71	Epstein-Barr Virus Strains With Latent Membrane Protein-1 Deletions: Prevalence in the Italian Population and High Association With Human Immunodeficiency Virus-Related Hodgkin's Disease. <i>Blood</i> , 1997, 89, 1723-1731.	1.4	46
72	Immunoglobulin gene repertoire in ocular adnexal lymphomas: hints on the nature of the antigenic stimulation. <i>Leukemia</i> , 2012, 26, 814-821.	7.2	45

#	ARTICLE	IF	CITATIONS
73	Cross-talk between Epstein-Barr virus and microenvironment in the pathogenesis of lymphomas. <i>Seminars in Cancer Biology</i> , 2015, 34, 58-69.	9.6	45
74	Characterization of overt B-cell lymphomas in patients with hepatitis C virus infection. <i>Blood</i> , 1997, 90, 776-82.	1.4	45
75	BRCA1 and BRCA2 genes: Role in hereditary breast and ovarian cancer in Italy. <i>Journal of Clinical Oncology</i> , 1999, 17, 5-9.		44
76	High incidence of monoclonal EBV episomes in Hodgkin's disease and anaplastic large cell ki-1 positive lymphomas in HIV-1 positive patients. <i>International Journal of Cancer</i> , 1993, 54, 53-59.	5.1	43
77	Virus-Specific Cytotoxic CD4+ T Cells for the Treatment of EBV-Related Tumors. <i>Journal of Immunology</i> , 2010, 184, 5895-5902.	0.8	43
78	GSK-3b inhibition: At the crossroad between Akt and mTOR constitutive activation to enhance cyclin D1 protein stability in mantle cell lymphoma. <i>Cell Cycle</i> , 2008, 7, 2813-2816.	2.6	42
79	Exploiting a new strategy to induce immunogenic cell death to improve dendritic cell-based vaccines for lymphoma immunotherapy. <i>Oncotarget</i> , 2017, 8, e1356964.	4.6	42
80	Widespread clonal B-cell disorder in Sjogren's syndrome predisposing to Helicobacter pylori-related gastric lymphoma. <i>Gastroenterology</i> , 1996, 110, 1969-1974.	1.3	41
81	Specific antibodies reacting with simian virus 40 capsid protein mimotopes in serum samples from healthy blood donors. <i>Human Immunology</i> , 2012, 73, 502-510.	2.4	41
82	NFATc2 Is a Potential Therapeutic Target in Human Melanoma. <i>Journal of Investigative Dermatology</i> , 2012, 132, 2652-2660.	0.7	41
83	Adoptive cell therapy against EBV-related malignancies: a survey of clinical results. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 1265-1294.	3.1	40
84	Isolated Bone Marrow Manifestation of HIV-Associated Hodgkin Lymphoma. <i>Modern Pathology</i> , 2002, 15, 1273-1278.	5.5	39
85	Infectious Agents in Mucosa-Associated Lymphoid Tissue-Type Lymphomas: Pathogenic Role and Therapeutic Perspectives. <i>Clinical Lymphoma and Myeloma</i> , 2006, 6, 289-300.	1.4	39
86	Elevated Serum Transforming Growth Factor $\beta$ 1 Levels in Epstein-Barr Virus-Associated Diseases and Their Correlation with Virus-Specific Immunoglobulin A (IgA) and IgM. <i>Journal of Virology</i> , 2000, 74, 2443-2446.	3.4	38
87	Chlamydia psittaci-eradicating antibiotic therapy in patients with advanced-stage ocular adnexal MALT lymphoma. <i>Annals of Oncology</i> , 2008, 19, 194-195.	1.2	38
88	Clinical value of Epstein-Barr virus DNA levels in peripheral blood samples of Italian patients with Undifferentiated Carcinoma of Nasopharyngeal Type. <i>Cancer Letters</i> , 2006, 233, 247-254.	7.2	37
89	Variable association between Chlamydia psittaci infection and ocular adnexal lymphomas: methodological biases or true geographical variations?. <i>Anti-Cancer Drugs</i> , 2008, 19, 761-765.	1.4	37
90	Short-term inhibition of TERT induces telomere length-independent cell cycle arrest and apoptotic response in EBV-immortalized and transformed B cells. <i>Cell Death and Disease</i> , 2016, 7, e2562-e2562.	6.3	36

#	ARTICLE	IF	CITATIONS
91	Hepatitis C virus within a malignant lymphoma lesion in the course of type II mixed cryoglobulinemia. <i>Blood</i> , 1995, 86, 1887-92.	1.4	36
92	Epstein-Barr virus infection and chronic lymphocytic leukemia: a possible progression factor?. <i>Infectious Agents and Cancer</i> , 2010, 5, 22.	2.6	34
93	Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. <i>Human Mutation</i> , 2012, 33, 690-702.	2.5	34
94	Microenvironment and HIV-related lymphomagenesis. <i>Seminars in Cancer Biology</i> , 2015, 34, 52-57.	9.6	34
95	A natural HIV p17 protein variant up-regulates the LMP-1 EBV oncoprotein and promotes the growth of EBV-infected B-lymphocytes: Implications for EBV-driven lymphomagenesis in the HIV setting. <i>International Journal of Cancer</i> , 2015, 137, 1374-1385.	5.1	34
96	Fighting Viral Infections and Virus-Driven Tumors with Cytotoxic CD4+ T Cells. <i>Frontiers in Immunology</i> , 2017, 8, 197.	4.8	34
97	Clinical and Antitumor Immune Responses in Relapsed/Refractory Follicular Lymphoma Patients after Intranodal Injections of IFN $\gamma$ -Dendritic Cells and Rituximab: a Phase I Clinical Trial. <i>Clinical Cancer Research</i> , 2019, 25, 5231-5241.	7.0	34
98	Retinoids irreversibly inhibit in vitro growth of Epstein-Barr virus-immortalized B lymphocytes. <i>Blood</i> , 1996, 88, 3147-3159.	1.4	33
99	Epstein-Barr virus and undifferentiated nasopharyngeal carcinoma: New immunobiological and molecular insights on a long-standing etiopathogenic association. <i>Advances in Cancer Research</i> , 2003, 87, 127-157.	5.0	33
100	hTERT inhibits the Epstein-Barr virus lytic cycle and promotes the proliferation of primary B lymphocytes: Implications for EBV-driven lymphomagenesis. <i>International Journal of Cancer</i> , 2007, 121, 576-587.	5.1	33
101	Retinoic acid inhibits the proliferative response induced by CD40 activation and interleukin-4 in mantle cell lymphoma. <i>Cancer Research</i> , 2005, 65, 587-95.	0.9	33
102	Is the Epstein-Barr Virus Involved in Hodgkin's Disease?. <i>Tumori</i> , 1989, 75, 345-350.	1.1	32
103	Retinoic acid-mediated growth arrest of EBV-immortalized B lymphocytes is associated with multiple changes in G1 regulatory proteins: p27Kip1 up-regulation is a relevant early event. <i>Oncogene</i> , 1998, 17, 1827-1836.	5.9	32
104	Spontaneous T cell responses to Epstein-Barr virus-encoded BARTF1 protein and derived peptides in patients with nasopharyngeal carcinoma: Bases for improved immunotherapy. <i>International Journal of Cancer</i> , 2008, 123, 1100-1107.	5.1	32
105	Prognostic significance of LINE-1 hypomethylation in oropharyngeal squamous cell carcinoma. <i>Clinical Epigenetics</i> , 2017, 9, 58.	4.1	32
106	The Italian multi-centre project on evaluation of MRI and other imaging modalities in early detection of breast cancer in subjects at high genetic risk. <i>Journal of Experimental and Clinical Cancer Research</i> , 2002, 21, 115-24.	0.4	32
107	Exploiting the Interplay between Innate and Adaptive Immunity to Improve Immunotherapeutic Strategies for Epstein-Barr-Virus-Driven Disorders. <i>Clinical and Developmental Immunology</i> , 2012, 1-19.	3.3	31
108	A Woman and Her Canary: A Tale of Chlamydiae and Lymphomas. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1418-1419.	6.3	30



#	ARTICLE	IF	CITATIONS
109	A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies. <i>Breast Cancer Research</i> , 2011, 13, R117.	5.0	30
110	Telomere/telomerase interplay in virus-driven and virus-independent lymphomagenesis: pathogenic and clinical implications. <i>Medicinal Research Reviews</i> , 2012, 32, 233-253.	10.5	30
111	The Epstein-Barr Virus (EBV) major envelope glycoprotein gp350/220-specific antibody reactivities in the sera of patients with different EBV-associated diseases. <i>International Journal of Cancer</i> , 1998, 79, 481-486.	5.1	29
112	Retinoids as Critical Modulators of Immune Functions: New Therapeutic Perspectives for Old Compounds. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2009, 9, 113-131.	1.2	29
113	Immunotherapy for EBV-associated malignancies. <i>International Journal of Hematology</i> , 2011, 93, 281-293.	1.6	29
114	The polymerase chain reaction detects B cell clonalities in patients with Sjögren's syndrome and suspected malignant lymphoma. <i>Journal of Rheumatology</i> , 1994, 21, 1497-501.	2.0	29
115	Simian Virus 40 Sequences in Human Lymphoblastoid B-Cell Lines. <i>Journal of Virology</i> , 2003, 77, 1595-1597.	3.4	28
116	Cross talk between EBV and telomerase: the role of TERT and NOTCH2 in the switch of latent/lytic cycle of the virus. <i>Cell Death and Disease</i> , 2015, 6, e1774-e1774.	6.3	28
117	Dissecting the Multiplicity of Immune Effects of Immunosuppressive Drugs to Better Predict the Risk of de novo Malignancies in Solid Organ Transplant Patients. <i>Frontiers in Oncology</i> , 2019, 9, 160.	2.8	28
118	Cancer Vaccines in Phase II/III Clinical Trials: State of the Art and Future Perspectives. <i>Current Cancer Drug Targets</i> , 2011, 11, 85-102.	1.6	27
119	Retinoic Acid/Alpha-Interferon Combination Inhibits Growth and Promotes Apoptosis in Mantle Cell Lymphoma through Akt-Dependent Modulation of Critical Targets. <i>Cancer Research</i> , 2012, 72, 1825-1835.	0.9	27
120	hTERT Inhibition Triggers Epstein-Barr Virus Lytic Cycle and Apoptosis in Immortalized and Transformed B Cells: A Basis for New Therapies. <i>Clinical Cancer Research</i> , 2013, 19, 2036-2047.	7.0	27
121	Hepatitis C virus-related hepatocellular carcinoma and B-cell lymphoma patients show a different profile of major histocompatibility complex class II alleles. <i>Human Immunology</i> , 2004, 65, 1397-1404.	2.4	26
122	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2015, 17, 61.	5.0	26
123	Local cytokine expression in the progression toward B cell malignancy in Sjögren's syndrome. <i>Journal of Rheumatology</i> , 1995, 22, 1674-80.	2.0	26
124	Human herpesvirus 6 in human immunodeficiency virus-infected individuals: Association with early histologic phases of lymphadenopathy syndrome but not with malignant lymphoproliferative disorders. , 1996, 48, 344-353.		25
125	Detection of nasopharyngeal carcinoma in Morocco (North Africa) using a multiplex methylation-specific PCR biomarker assay. <i>Clinical Epigenetics</i> , 2015, 7, 89.	4.1	25
126	Association of Epstein-Barr virus genome with mixed cellularity and cellular phase nodular sclerosis Hodgkin's disease subtypes. <i>Annals of Oncology</i> , 1992, 3, 307-310.	1.2	24



#	ARTICLE	IF	CITATIONS
127	Subtypes of epstein-barr virus in HIV-1-associated and HIV-1-unrelated hodgkin's disease cases. <i>International Journal of Cancer</i> , 1993, 54, 895-898.	5.1	24
128	Low incidence ofBRCA1 mutations among Italian families with breast and ovarian cancer. <i>International Journal of Cancer</i> , 1998, 78, 581-586.	5.1	24
129	Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies. <i>Oncotarget</i> , 2016, 7, 57327-57350.	1.8	24
130	Demonstration of a unique Epstein-Barr virus-positive cellular clone in metachronous multiple localizations of Hodgkin's disease. <i>American Journal of Pathology</i> , 1993, 142, 33-8.	3.8	24
131	Characteristics of EBV-infected cells in HIV-related lymphadenopathy: Implications for the pathogenesis of EBV-associated and EBV-unrelated lymphomas of HIV-seropositive individuals. <i>International Journal of Cancer</i> , 1995, 63, 652-659.	5.1	23
132	Simian Immunodeficiency Virus and Human Immunodeficiency Virus Type 1 Matrix Proteins Specify Different Capabilities To Modulate B Cell Growth. <i>Journal of Virology</i> , 2014, 88, 5706-5717.	3.4	23
133	Multiple viral infections in primary effusion lymphoma: a model of viral cooperation in lymphomagenesis. <i>Expert Review of Hematology</i> , 2017, 10, 505-514.	2.2	23
134	Enhancing chimeric antigen receptor Tâ€cell immunotherapy against cancer using a nanoemulsionâ€based vaccine targeting crossâ€presenting dendritic cells. <i>Clinical and Translational Immunology</i> , 2020, 9, e1157.	3.8	23
135	Characterization of Overt B-Cell Lymphomas in Patients With Hepatitis C Virus Infection. <i>Blood</i> , 1997, 90, 776-782.	1.4	23
136	Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease. <i>Blood</i> , 1995, 86, 1493-501.	1.4	23
137	Retinoic acid stabilizes p27Kip1 in EBV-immortalized lymphoblastoid B cell lines through enhanced proteasome-dependent degradation of the p45Skp2 and Cks1 proteins. <i>Oncogene</i> , 2005, 24, 2483-2494.	5.9	22
138	HLA DR-DQ combination associated with the increased risk of developing human HCV positive non-Hodgkin's lymphoma is related to the type II mixed cryoglobulinemia. <i>Tissue Antigens</i> , 2010, 75, 127-135.	1.0	22
139	Retinoic acid induces persistent, RAR?-mediated anti-proliferative responses in Epstein-Barr virus-immortalized b lymphoblasts carrying an activated c-myc oncogene but not in Burkitt's lymphoma cell lines. , 2000, 86, 375-384.		21
140	High serum levels of soluble CD40-L in patients with undifferentiated nasopharyngeal carcinoma: pathogenic and clinical relevance. <i>Infectious Agents and Cancer</i> , 2007, 2, 5.	2.6	21
141	B-Cell Lymphomas Associated With HCV Infection. <i>Gastroenterology</i> , 2007, 132, 1205-1207.	1.3	21
142	Reverse immunoeediting: When immunity is edited by antigen. <i>Immunology Letters</i> , 2016, 175, 16-20.	2.5	21
143	N-myc activation by proviral insertion in MCF 247-induced murine T-cell lymphomas. <i>Oncogene</i> , 1989, 4, 1009-14.	5.9	21
144	Genetic insights into the disease mechanisms of type II mixed cryoglobulinemia induced by hepatitis C virus. <i>Digestive and Liver Disease</i> , 2007, 39, S65-S71.	0.9	20

#	ARTICLE	IF	CITATIONS
145	Role of the HLA Class II: HCV-Related Disorders. <i>Annals of the New York Academy of Sciences</i> , 2007, 1107, 308-318.	3.8	19
146	Broadening Specificity and Enhancing Cytotoxicity of Adoptive T Cells for Nasopharyngeal Carcinoma Immunotherapy. <i>Cancer Immunology Research</i> , 2016, 4, 431-440.	3.4	19
147	An Ex Vivo Human Tumor Assay Shows Distinct Patterns of EGFR Trafficking in Squamous Cell Carcinoma Correlating to Therapeutic Outcomes. <i>Journal of Investigative Dermatology</i> , 2019, 139, 213-223.	0.7	19
148	Uncoupling of growth inhibition and differentiation in dexamethasone-treated human rhabdomyosarcoma cells. <i>British Journal of Cancer</i> , 1993, 67, 674-679.	6.4	18
149	Undifferentiated nasopharyngeal carcinoma from a nonendemic area: Protective role of HLA allele products presenting conserved EBV epitopes. <i>International Journal of Cancer</i> , 2009, 125, 1358-1364.	5.1	18
150	Central nervous system marginal zone B-cell lymphoma associated with <i>Chlamydomyxa psittaci</i> infection. <i>Human Pathology</i> , 2011, 42, 738-742.	2.0	18
151	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 117-134.	2.5	18
152	Emotional impact on the results of BRCA1 and BRCA2 genetic test: an observational retrospective study. <i>Hereditary Cancer in Clinical Practice</i> , 2017, 15, 16.	1.5	18
153	The Relevance of VDJ PCR Protocols in Detecting B-Cell Clonal Expansion in Lymphomas and Other Lymphoproliferative Disorders. <i>Tumori</i> , 1995, 81, 405-409.	1.1	17
154	Activation of Infiltrating Cytotoxic T Lymphocytes and Lymphoma Cell Apoptotic Rates in Gastric MALT Lymphomas. <i>American Journal of Pathology</i> , 1999, 155, 823-829.	3.8	17
155	Innovative Therapeutic Strategies for Effective Treatment of Brain Metastases. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1280.	4.1	17
156	Phospholipid scramblase 1 as a critical node at the crossroad between autophagy and apoptosis in mantle cell lymphoma. <i>Oncotarget</i> , 0, 7, 41913-41928.	1.8	17
157	Identification and characterization of an Epstein-Barr virus-specific T-cell response in the pathologic tissue of a patient with Hodgkin's disease. <i>Cancer Research</i> , 1995, 55, 3675-81.	0.9	17
158	Retinoic Acid Analogues Inhibit Human Herpesvirus 8 Replication. <i>Antiviral Therapy</i> , 2008, 13, 199-210.	1.0	17
159	Characterization of Epstein-Barr Virus Genotype in AIDS-Related Non-Hodgkin's Lymphoma. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 19-26.	1.1	16
160	Tracking of the origin of recurrent mutations of the BRCA1 and BRCA2 genes in the North-East of Italy and improved mutation analysis strategy. <i>BMC Medical Genetics</i> , 2016, 17, 11.	2.1	16
161	HCV-related liver and lymphoproliferative diseases: association with polymorphisms of IL28B and TLR2. <i>Oncotarget</i> , 2016, 7, 37487-37497.	1.8	16
162	High prevalence of <i>Chlamydomyxa psittaci</i> subclinical infection in Italian patients with Sjögren's syndrome and parotid gland marginal zone B-cell lymphoma of MALT-type. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, 61-5.	0.8	16

#	ARTICLE	IF	CITATIONS
163	Nuclear oncogene amplification or rearrangement is not involved in human colorectal malignancies. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1988, 24, 1321-1328.	0.7	15
164	Genetic and epigenetic changes linked to <i>Chlamydomonas reinhardtii</i> -associated ocular adnexal lymphomas. <i>Hematological Oncology</i> , 2010, 28, 1-2.	1.7	15
165	A single amino acid substitution confers B-cell clonogenic activity to the HIV-1 matrix protein p17. <i>Scientific Reports</i> , 2017, 7, 6555.	3.3	15
166	Epstein-Barr Virus Strains With Latent Membrane Protein-1 Deletions: Prevalence in the Italian Population and High Association With Human Immunodeficiency Virus-Related Hodgkin's Disease. <i>Blood</i> , 1997, 89, 1723-1731.	1.4	15
167	Toll-Like Receptor 1/2 and 5 Ligands Enhance the Expression of Cyclin D1 and D3 and Induce Proliferation in Mantle Cell Lymphoma. <i>PLoS ONE</i> , 2016, 11, e0153823.	2.5	15
168	Cancer, Aging and Immune Reconstitution. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2013, 13, 1310-1324.	1.7	15
169	Epstein-Barr virus in the pathogenesis of Hodgkin's disease. <i>Biomedicine and Pharmacotherapy</i> , 1998, 52, 13-25.	5.6	14
170	Bidirectional induction of the cognate receptor-ligand $\alpha 4$ /VCAM-1 pair defines a novel mechanism of tumor intravasation. <i>Blood</i> , 2000, 95, 2397-2406.	1.4	14
171	Latent Membrane Protein 1 Deletion Mutants Accumulate in Reed-Sternberg Cells of Human Immunodeficiency Virus-Related Hodgkin's Lymphoma. <i>Journal of Virology</i> , 2005, 79, 2643-2649.	3.4	14
172	Bacteria-eradicating therapy for ocular adnexal MALT lymphoma: questions for an open international prospective trial. <i>Annals of Oncology</i> , 2006, 17, 1721-1722.	1.2	14
173	Proteins specifically hyperexpressed in a coeliac disease patient with aberrant T cells. <i>Clinical and Experimental Immunology</i> , 2007, 148, 402-409.	2.6	14
174	IGKV3 Proteins as Candidate "Off-the-Shelf" Vaccines for Kappa-Light Chain-Restricted B-Cell Non-Hodgkin Lymphomas. <i>Clinical Cancer Research</i> , 2012, 18, 4080-4091.	7.0	14
175	Glucocorticoids promote the proliferation and antagonize the retinoic acid-mediated growth suppression of Epstein-Barr virus-immortalized B lymphocytes. <i>Blood</i> , 2000, 96, 711-718.	1.4	13
176	Phenotypic features and genetic characterization of male breast cancer families: identification of two recurrent BRCA2 mutations in north-east of Italy. <i>BMC Cancer</i> , 2006, 6, 156.	2.6	13
177	Exposure to animals and increased risk of marginal zone B-cell lymphomas of the ocular adnexae. <i>British Journal of Cancer</i> , 2012, 106, 966-969.	6.4	13
178	Serologic investigation of undifferentiated nasopharyngeal carcinoma and simian virus 40 infection. <i>Head and Neck</i> , 2016, 38, 232-236.	2.0	13
179	A BARTF1-specific mAb as a new immunotherapeutic tool for the management of EBV-related tumors. <i>Oncotarget</i> , 2017, 8, e1304338.	4.6	13
180	Protein glycosylation in head and neck cancers: From diagnosis to treatment. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1874, 188422.	7.4	13

#	ARTICLE	IF	CITATIONS
181	Aids-related B-cell non-Hodgkin's lymphomas in direct blood-stream HIV-infected patients: Pathogenesis and differentiation features. <i>International Journal of Cancer</i> , 1990, 45, 883-888.	5.1	12
182	Association between B-type Epstein-Barr virus and Hodgkin's disease in immunocompromised patients [letter; comment]. <i>Blood</i> , 1993, 82, 328-330.	1.4	12
183	Biologically relevant phenotypic changes and enhanced growth properties induced in B lymphocytes by an EBV strain derived from a histologically aggressive Hodgkin's disease. , 1999, 80, 240-249.		12
184	Characterization of Antibodies Directed against the Immunoglobulin Light Î¸ Chain Variable Chain Region (VK) of Hepatitis C Virusâ€Related Typeâ€ Mixed Cryoglobulinemia and Bâ€Cell Proliferations. <i>Annals of the New York Academy of Sciences</i> , 2009, 1173, 152-160.	3.8	12
185	Immune signatures in human PBMCs of idiopathic vaccine for HCV-related lymphoproliferative disorders. <i>Journal of Translational Medicine</i> , 2010, 8, 18.	4.4	12
186	Breast Cancer and Simian Virus 40 Infection. <i>Epidemiology</i> , 2013, 24, 464-465.	2.7	12
187	Targeting Replication Stress Using CHK1 Inhibitor Promotes Innate and NKT Cell Immune Responses and Tumour Regression. <i>Cancers</i> , 2021, 13, 3733.	3.7	12
188	Retinoic acid analogues inhibit human herpesvirus 8 replication. <i>Antiviral Therapy</i> , 2008, 13, 199-209.	1.0	12
189	Frequent detection of human herpesvirus 6 DNA in HIV-associated lymphadenopathy. <i>Lancet, The</i> , 1994, 344, 543.	13.7	11
190	EBV-Associated Tumors: Pathogenetic Insights for Improved Disease Monitoring and Treatment. <i>Current Cancer Therapy Reviews</i> , 2005, 1, 27-44.	0.3	11
191	Epstein-Barr virus and telomerase: from cell immortalization to therapy. <i>Infectious Agents and Cancer</i> , 2014, 9, 8.	2.6	11
192	Reprogramming the anti-tumor immune response via CRISPR genetic and epigenetic editing. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 21, 592-606.	4.1	11
193	Type 2 Epstein-Barr Virus Genome and Latent Membrane Protein-1 Expression in a T-Cell-Rich Lymphoma of Probable B-Cell Lineage. <i>American Journal of Clinical Pathology</i> , 1993, 100, 541-549.	0.7	10
194	Serum Antibody Response to Lytic and Latent Epstein-Barr Virus Antigens in Undifferentiated Nasopharyngeal Carcinoma Patients from an Area of Nonendemicity. <i>Vaccine Journal</i> , 2007, 14, 435-441.	3.1	10
195	NKT Cellâ€Driven Enhancement of Antitumor Immunity Induced by Clec9a-Targeted Tailorable Nanoemulsion. <i>Cancer Immunology Research</i> , 2019, 7, 952-962.	3.4	10
196	Epstein-Barr virus and undifferentiated nasopharyngeal carcinoma: New immunobiological and molecular insights on a long-standing etiopathogenic association. <i>Advances in Cancer Research</i> , 2003, 87, 127-157.	5.0	10
197	Is the Epstein-Barr virus involved in Hodgkin's disease?. <i>Tumori</i> , 1989, 75, 345-50.	1.1	10
198	Cellular and molecular bases of B-cell clonal expansions. <i>Clinical and Experimental Rheumatology</i> , 1996, 14 Suppl 14, S3-13.	0.8	10

#	ARTICLE	IF	CITATIONS
199	Proto-oncogene allelic variations in human squamous cell carcinomas of the larynx. <i>European Archives of Oto-Rhino-Laryngology</i> , 1991, 248, 279-85.	1.6	9
200	Transformation-Associated Epstein-Barr Virus Antigens as Targets for Immune Attack. <i>Annals of the New York Academy of Sciences</i> , 1993, 690, 86-100.	3.8	9
201	Detection of DNA of <i>Chlamydomytila psittaci</i> in subjects with psoriasis: a casual or a causal link?. <i>British Journal of Dermatology</i> , 2012, 167, 926-928.	1.5	9
202	Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients. <i>BMC Cancer</i> , 2014, 14, 954.	2.6	9
203	Optimizing checkpoint inhibitors therapy for relapsed or progressive classic Hodgkin lymphoma by multiplex immunohistochemistry of the tumor microenvironment. <i>Cancer Medicine</i> , 2019, 8, 3012-3016.	2.8	9
204	Lymphomagenic properties of a HIV p17 variant derived from a splenic marginal zone lymphoma occurred in a HIV-1 infected patient. <i>Hematological Oncology</i> , 2019, 37, 176-184.	1.7	9
205	Epstein-Barr virus strains with latent membrane protein-1 deletions: prevalence in the Italian population and high association with human immunodeficiency virus-related Hodgkin's disease. <i>Blood</i> , 1997, 89, 1723-31.	1.4	9
206	Successes, failures and new perspectives of idiotypic vaccination for B-cell non-Hodgkin lymphomas. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1078-1083.	3.3	8
207	Targeted DNA vaccines eliciting crossreactive anti-idiotypic antibody responses against human B cell malignancies in mice. <i>Journal of Translational Medicine</i> , 2014, 12, 207.	4.4	8
208	Detection of HIV-1 Matrix Protein p17 Quasispecies Variants in Plasma of Chronic HIV-1 Infected Patients by Ultra-Deep Pyrosequencing. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, 332-339.	2.1	8
209	What's New in the Biology and Treatment of Undifferentiated Carcinoma of Nasopharyngeal Type?. <i>Acta Oto-Laryngologica</i> , 2001, 121, 884-895.	0.9	8
210	Teaching digital pathology: The international school of digital pathology and proposed syllabus. <i>Journal of Pathology Informatics</i> , 2017, 8, 27.	1.7	8
211	In vivo phenotypic characteristics of AKR T-cell lymphomas with different leukemic potential: Possible role of $\alpha 4 \beta 7$ integrin in the progression towards the leukemic phenotype. <i>International Journal of Cancer</i> , 1994, 56, 560-567.	5.1	7
212	Inhibition of oxidative phosphorylation underlies the antiproliferative and proapoptotic effects of mofarotene (Ro 40-8757) in Burkitt's lymphoma cells. <i>Oncogene</i> , 2003, 22, 906-918.	5.9	7
213	Therapeutic management of ocular adnexal MALT lymphoma. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 1073-1083.	1.8	7
214	Prevalence of chlamydial infection in a series of 108 primary cutaneous lymphomas. <i>British Journal of Dermatology</i> , 2012, 166, 1121-1123.	1.5	7
215	Functional Avidity-Driven Activation-Induced Cell Death Shapes CTL Immunodominance. <i>Journal of Immunology</i> , 2014, 193, 4704-4711.	0.8	7
216	Alpha 4 beta 7 integrin expression is associated with the leukemic evolution of human and murine T-cell lymphoblastic lymphomas. <i>American Journal of Pathology</i> , 1997, 150, 1595-605.	3.8	7

#	ARTICLE	IF	CITATIONS
217	Retinoids irreversibly inhibit in vitro growth of Epstein-Barr virus-immortalized B lymphocytes. <i>Blood</i> , 1996, 88, 3147-59.	1.4	7
218	Bidirectional induction of the cognate receptor-ligand alpha4/VCAM-1 pair defines a novel mechanism of tumor intravasation. <i>Blood</i> , 2000, 95, 2397-406.	1.4	7
219	Establishment and characterization of a leukemic murine cell line derived from MCF 247 MuLV-induced T-cell lymphoma. <i>International Journal of Cancer</i> , 1990, 45, 928-934.	5.1	6
220	Pathogenesis of Human Reactive-Appearing «Non-Monomorphous» Malignant Lymphoproliferative Disorders: A Hypothesis. <i>Tumori</i> , 1992, 78, 221-227.	1.1	6
221	Target therapy in elderly breast cancer patients. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 83, 422-431.	4.4	6
222	B-cell clonogenic activity of HIV-1 p17 variants is driven by PAR1-mediated EGF transactivation. <i>Cancer Gene Therapy</i> , 2021, 28, 649-666.	4.6	6
223	Scientifically based combination therapies with immuno-oncology checkpoint inhibitors. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1711-1725.	2.4	6
224	Characterization of Immune Cell Subsets of Tumor Infiltrating Lymphocytes in Brain Metastases. <i>Biology</i> , 2021, 10, 425.	2.8	6
225	Association of Epstein-Barr Virus with Hodgkin's Disease. <i>Infectious Agents and Pathogenesis</i> , 1995, , 375-393.	0.1	6
226	The relevance of VDJ PCR protocols in detecting B-cell clonal expansion in lymphomas and other lymphoproliferative disorders. <i>Tumori</i> , 1995, 81, 405-9.	1.1	6
227	<i>Chlamydia psittaci</i> subclinical infection in chronic polyarthritis. <i>Clinical and Experimental Rheumatology</i> , 2011, 29, 977-82.	0.8	6
228	Analysis of human leukocyte antigen associations in human papillomavirus "positive and "negative head and neck cancer: Comparison with cervical cancer. <i>Cancer</i> , 2022, 128, 1937-1947.	4.1	6
229	A coordinated proto-oncogene expression characterizes MCF 247 murine leukemia virus-induced T-cell lymphomas irrespectively of proviral insertion affecting myc loci. <i>Leukemia Research</i> , 1990, 14, 549-558.	0.8	5
230	<i>In Vitro</i> Effects of Retinoids on the Proliferation and Differentiation Features of Epstein-Barr Virus-Immortalized B Lymphocytes. <i>Leukemia and Lymphoma</i> , 1998, 29, 269-281.	1.3	5
231	Reply to the article "Hepatitis C virus (HCV) infection and MALT-type ocular adnexal lymphoma (OAL)" by P. Arnaud, M.-C. Escande, M. Lecuit et al. ( <i>Ann Oncol</i> doi:10.1093/annonc/mdl369). <i>Annals of Oncology</i> , 2007, 18, 401-403.	1.2	5
232	Differential down-modulation of HLA class I and II molecule expression on human tumor cell lines upon in vivo transfer. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 1639-1645.	4.2	5
233	Remodeling of the epitope repertoire of a candidate idioype vaccine by targeting to lysosomal degradation in dendritic cells. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 881-892.	4.2	5
234	A CXCR1 haplotype hampers HIV-1 matrix protein p17 biological activity. <i>Aids</i> , 2014, 28, 2355-2364.	2.2	5



#	ARTICLE	IF	CITATIONS
235	Predictive Value of FcR Polymorphisms. <i>JAMA Oncology</i> , 2017, 3, 342.	7.1	5
236	Will Next-Generation Immunotherapy Overcome the Intrinsic Diversity and Low Immunogenicity of Sarcomas to Improve Clinical Benefit?. <i>Cancers</i> , 2020, 12, 3392.	3.7	5
237	Editorial: Dendritic Cell-Based Immunotherapy in Solid and Haematologic Tumors. <i>Frontiers in Immunology</i> , 2020, 11, 507.	4.8	5
238	Personalized Immunotherapy in Follicular Lymphoma By Intranodal IFN-Dendritic-Cell Combined to Anti-CD20 Antibody. <i>Blood</i> , 2016, 128, 2976-2976.	1.4	5
239	Association between B-type Epstein-Barr virus and Hodgkin's disease in immunocompromised patients. <i>Blood</i> , 1993, 82, 328-30.	1.4	5
240	T cell receptor repertoire in B cell lymphoproliferative lesions in primary Sjögren's syndrome. <i>Journal of Rheumatology</i> , 1999, 26, 1101-9.	2.0	5
241	Lack of Fas and Fas-L mutations in patients with lymphoproliferative disorders associated with Sjögren's syndrome and type II mixed cryoglobulinemia. <i>Clinical and Experimental Rheumatology</i> , 1999, 17, 339-42.	0.8	5
242	Degree of immune suppression and risk of HIV-related Hodgkin lymphoma: time points matter. <i>Blood</i> , 2009, 114, 2354-2354.	1.4	4
243	Impact of $\beta$ -chain cytokines on EBV-specific T cell cultures. <i>Journal of Translational Medicine</i> , 2010, 8, 121.	4.4	4
244	Mood state profile and coping strategies after BRCA-1/2 genetic test disclosure: a retrospective study in Italy. <i>Supportive Care in Cancer</i> , 2011, 19, 733-735.	2.2	4
245	Understanding the immuno-biology of oesophageal adenocarcinoma: Towards improved therapeutic approaches. <i>Cancer Treatment Reviews</i> , 2021, 98, 102219.	7.7	4
246	Multiparametric Analyses of Human PBMCs Loaded Ex Vivo with a Candidate Idiotype Vaccine for HCV-Related Lymphoproliferative Disorders. <i>PLoS ONE</i> , 2012, 7, e44870.	2.5	4
247	Protein Expression Profile of Celiac Disease Patient with Aberrant T Cell by Two-dimensional Difference Gel Electrophoresis. <i>Annals of the New York Academy of Sciences</i> , 2007, 1109, 429-440.	3.8	3
248	Selecting for BRCA1 testing using a combination of homogeneous selection criteria and immunohistochemical characteristics of breast cancers. <i>BMC Cancer</i> , 2009, 9, 360.	2.6	3
249	Bugs and marginal zone lymphoma of the ocular adnexae: is the future already here?. <i>Blood</i> , 2009, 114, 3499-3499.	1.4	3
250	Marginal zone B-cell lymphoma of the conjunctiva. <i>Expert Review of Ophthalmology</i> , 2010, 5, 177-188.	0.6	3
251	Predictive Value of CD8 Expression and FoxP3 Methylation in Nasopharyngeal Carcinoma Patients Treated with Chemoradiotherapy in a Non-endemic Area. <i>Pathology and Oncology Research</i> , 2020, 26, 2459-2467.	1.9	3
252	<i>PDCD1</i> and <i>IFNL4</i> genetic variants and risk of developing hepatitis C virus-related diseases. <i>Liver International</i> , 2021, 41, 133-149.	3.9	3



#	ARTICLE	IF	CITATIONS
253	Glucocorticoids promote the proliferation and antagonize the retinoic acid-mediated growth suppression of Epstein-Barr virus-immortalized B lymphocytes. <i>Blood</i> , 2000, 96, 711-718.	1.4	3
254	Glucocorticoids promote the proliferation and antagonize the retinoic acid-mediated growth suppression of Epstein-Barr virus-immortalized B lymphocytes. <i>Blood</i> , 2000, 96, 711-8.	1.4	3
255	Genotypic and immunohistological demonstration of the progression of an unusual reactive-like B-cell lymphoproliferative disorder to a high grade diffuse lymphoma. <i>Human Pathology</i> , 1995, 26, 348-354.	2.0	2
256	Unconventional therapies in ocular adnexal lymphomas. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1341-1343.	2.4	2
257	Polymerase chain reaction to assess B-cell clonality in clinical conditions at risk for B-cell malignancy. <i>Transplantation Proceedings</i> , 1994, 26, 3229-32.	0.6	2
258	Correspondence re: Samowitz et al., Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. <i>Cancer Epidemiol. Biomark. Prev.</i> , 10: 917-923, 2001. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2002, 11, 499; author reply 499-500.	2.5	2
259	Retinoic acid inhibits IL-6-dependent but not constitutive STAT3 activation in Epstein-Barr virus-immortalized B lymphocytes. <i>International Journal of Oncology</i> , 2004, 25, 345-55.	3.3	2
260	No association between polyomaviruses and primary central nervous system lymphomas of HIV-seronegative and HIV-positive patients. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004, 13, 1819-20.	2.5	2
261	In-depth analysis of compartmentalization of HIV-1 matrix protein p17 in PBMC and plasma. <i>New Microbiologica</i> , 2017, 40, 58-61.	0.1	2
262	KIR-HLA Functional Repertoire Influences Trastuzumab Efficiency in Patients With HER2-Positive Breast Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 791958.	4.8	2
263	Genotypic and Immunophenotypic Characterization of Two Human Light Chain-Only B-Cell Non-Hodgkin's Lymphomas. <i>American Journal of Clinical Pathology</i> , 1990, 94, 390-396.	0.7	1
264	On the Biological Role of T-lymphocytes in T-cell-rich B-cell Lymphomas. <i>American Journal of Clinical Pathology</i> , 1995, 104, 231.1-231.	0.7	1
265	Microsatellite Instability in Colorectal Cancer: Prognostic, Predictive or Both?. <i>American Journal of Pathology</i> , 2002, 160, 384-386.	3.8	1
266	Ruolo del virus di Epstein-Barr nella patogenesi dei disordini linfoproliferativi post-trapianto. <i>Microbiologia Medica</i> , 2003, 18, .	0.1	1
267	Retinoic acid inhibits IL-6-dependent but not constitutive STAT3 activation in Epstein-Barr virus-immortalized B lymphocytes. <i>International Journal of Oncology</i> , 2004, 25, 345.	3.3	1
268	Genetic and Epigenetic Mechanisms in Gastric Cancer. <i>Current Clinical Pathology</i> , 2019, , 25-40.	0.0	1
269	Immunomodulation and Immunotherapy for Gastric Cancer. <i>Current Clinical Pathology</i> , 2019, , 189-212.	0.0	1
270	Biological Predictors of De Novo Tumors in Solid Organ Transplanted Patients During Oncological Surveillance: Potential Role of Circulating TERT mRNA. <i>Frontiers in Oncology</i> , 2021, 11, 772348.	2.8	1

#	ARTICLE	IF	CITATIONS
271	Chlamydia Psittaci-Eradicating Antibiotic Therapy as a Potential Therapeutic Strategy Against Marginal Zone B-Cell Lymphoma of the Ocular Adnexa.. Blood, 2004, 104, 3274-3274.	1.4	1
272	Final Results of a Multicenter Phase II Trial with Translational Elements to Investigate the Possible Infective Causes of Ocular Adnexal Marginal Zone B-Cell Lymphoma (OAMZL) with Particular Reference to Chlamydia Species and the Efficacy of Doxycycline As First-Line Lymphoma Treatment (the Tj ETQq0 0 0 rgBT / Overlock 10	1.4	1
273	Adhesion molecule expression does not influence the leukemic behavior of murine T-cell lymphomas. Leukemia, 1992, 6 Suppl 3, 101S-105S.	7.2	1
274	Pathogenesis of malignant lymphomas in intravenous drug-abuser, HIV-infected patients. Cancer Detection and Prevention, 1990, 14, 661-8.	2.1	1
275	Can a specifically-aimed pathologic classification overcome the difficulties in defining HIV-associated lymphomas?. Pathologica, 1995, 87, 4-13.	3.4	1
276	Immune Activation, Exhaustion and Senescence Profiles as Possible Predictors of Cancer in Liver Transplanted Patients. Frontiers in Oncology, 0, 12, .	2.8	1
277	HIV-1 mutants expressing B cell clonogenic matrix protein p17 variants are increasing their prevalence worldwide. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	1
278	An Eco RI restriction length polymorphism at the murine L-myc locus. Nucleic Acids Research, 1988, 16, 11853-11853.	14.5	0
279	Activation by Point Mutation of Ki-ras Gene Occurring in Transfected Human Normal dna. Tumori, 1988, 74, 499-506.	1.1	0
280	210 Phospholipid Scramblase 1 Sensitizes Mantle Cell Lymphoma to Apoptosis Induced by Several Drugs. European Journal of Cancer, 2012, 48, S51.	2.8	0
281	936 The Interplay Between Telomerase and Epstein Barr Virus (EBV) â€“Silencing of HTERT Induces the EBV Lytic Cycle. European Journal of Cancer, 2012, 48, S225.	2.8	0
282	1084 Neoadjuvant Trastuzumab and Paclitaxel Combination Induces a High Rate of Pathological Complete Responses in Locally Advanced Breast Cancer by Exploiting Host Antitumor Immunity. European Journal of Cancer, 2012, 48, S261.	2.8	0
283	1085 Generation of EBV-specific CTL Lines Enriched in BARF1 Specificities for Improved Adoptive Immunotherapy of Nasopharyngeal Carcinoma. European Journal of Cancer, 2012, 48, S261.	2.8	0
284	1086 IGHV1-69 as a Promising Candidate for the Development of a Shared Immunotherapy to B-cell Lymphomas. European Journal of Cancer, 2012, 48, S261-S262.	2.8	0
285	Ocular Adnexal Lymphoma of MALT-Type and Its Association with Chlamydomphila psittaci Infection. , 2012, , 139-163.		0
286	Stereotactic Ablative Radiation Therapy (SABR) for Oligometastatic Breast Cancer Patients: Investigating the Immune Profile to Identify Predictive Biomarkers. International Journal of Radiation Oncology Biology Physics, 2014, 90, S769.	0.8	0
287	157â€ƒPathogenesis of Epstein-Barr Virus-driven lymphomas of HIV+ patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 67.	2.1	0
288	Role of non-coding RNAs in resistance to targeted therapies in cutaneous melanoma. European Journal of Cancer, 2016, 69, S74.	2.8	0

#	ARTICLE	IF	CITATIONS
289	Role of the HIV matrix protein p17 in EBV-driven lymphomagenesis. <i>European Journal of Cancer</i> , 2016, 61, S67-S68.	2.8	0
290	Prognostic Significance of Immune Microenvironmental Factors in Undifferentiated Nasopharyngeal Carcinoma Patients Treated with Chemoradiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, e242.	0.8	0
291	INTRANODAL TREATMENT WITH IFN $\gamma$ -DENDRITIC CELLS AND RITUXIMAB INDUCES SYSTEMIC CLINICAL RESPONSE AND ENDOGENOUS VACCINATION AGAINST FOLLICULAR LYMPHOMA: FINAL RESULT OF A PHASE I STUDY. <i>Hematological Oncology</i> , 2019, 37, 317-318.	1.7	0
292	831 Bortezomib-induced immunogenic cell death enhances immune response in melanoma. <i>Journal of Investigative Dermatology</i> , 2019, 139, S143.	0.7	0
293	456 Bortezomib induces immunogenic cell death in melanoma and enhances immune responses in vivo. <i>Journal of Investigative Dermatology</i> , 2019, 139, S293.	0.7	0
294	Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 1. <i>Hemato</i> , 2020, 1, 10-22.	0.6	0
295	Recent Advancements in Hematology: Knowledge, Methods and Dissemination. <i>Hemato</i> , 2020, 1, 5-6.	0.6	0
296	Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 2. <i>Hemato</i> , 2021, 2, 79-88.	0.6	0
297	Abstract 1443: CHK1 inhibitor +low dose hydroxyurea triggers immunogenic cell death and immunostimulatory cytokine expression to drive an anti-tumor immune response. , 2021, , .		0
298	Abstract 272: Glycomics: Protein glycosylation changes in the pathogenesis of head and neck cancer. , 2021, , .		0
299	Bidirectional induction of the cognate receptor-ligand $\alpha 4$ /VCAM-1 pair defines a novel mechanism of tumor intravasation. <i>Blood</i> , 2000, 95, 2397-2406.	1.4	0
300	Proteomic Profile of Human Gut Biopsies from Celiac Patients with and without Severe Complications.. <i>Blood</i> , 2006, 108, 3899-3899.	1.4	0
301	HER2 guided neoadjuvant treatment of advanced breast cancer: Clinico-biological correlations. <i>Journal of Clinical Oncology</i> , 2008, 26, 11559-11559.	1.6	0
302	Immunoglobulin Gene Repertoire in Ocular Adnexa Lymphomas (OAL): Hints on the Nature of the Antigenic Stimulation. <i>Blood</i> , 2008, 112, 623-623.	1.4	0
303	A phase II trial addressing the prevalence of chlamydial infection and eradication efficacy of antibiotic therapy in marginal zone lymphoma (OAMZL) and other lymphoproliferative disorders of the ocular adnexae (LPDOA).. <i>Journal of Clinical Oncology</i> , 2010, 28, e18520-e18520.	1.6	0
304	Immunologic profiling and clinical outcome in HER2+ breast cancer patients treated in a neoadjuvant phase II study: A step forward to understand trastuzumab activity.. <i>Journal of Clinical Oncology</i> , 2011, 29, e11083-e11083.	1.6	0
305	P3-14-25: Neoadjuvant Trastuzumab and Paclitaxel Combination Induces a High Rate of Pathological Complete Responses in Locally Advanced Breast Cancer by Exploiting Host Antitumor Immunity.. , 2011, , .		0
306	Association of Human Herpesvirus 6 with Human Tumors. <i>Infectious Agents and Pathogenesis</i> , 1995, , 313-326.	0.1	0

#	ARTICLE	IF	CITATIONS
307	Abstract 1196: Epigenetic drugs modulate long noncoding RNAs expression in BRAF inhibitor-resistant melanoma. , 2017, , .		0
308	Abstract 1839: Suppression of Spry1 sensitizes cutaneous melanoma to BRAF-targeted therapy. , 2018, , .		0
309	High Response Rate in Relapsed/Refractory Follicular Lymphoma Following Personalised Immunotherapy with Intranodal IFN-Alpha-Dendritic-Cell and Rituximab. Blood, 2018, 132, 5334-5334.	1.4	0
310	Abstract B12: Examining EGFR-mediated PI3K/Akt pathway in combination therapy of cetuximab and dynamin inhibition. , 2020, , .		0
311	Pathogenesis of human reactive-appearing "non-monomorphous" malignant lymphoproliferative disorders: a hypothesis. Tumori, 1992, 78, 221-7.	1.1	0
312	Activation by point mutation of Ki-ras gene occurring in transfected human normal DNA. Tumori, 1988, 74, 499-506.	1.1	0
313	The role of molecular analyses of B-cell and T-cell clonality in the study of B-cell lymphomagenesis. Clinical and Experimental Rheumatology, 1996, 14 Suppl 14, S21-9.	0.8	0